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CHAPTER 1
INTRODUCTION

The Need for a Blood Substitute
The search for a blood substitute has been an ongoing research area for
at least the last twenty-five years due to problems within the blood supply .1 A
blood substitute would eliminate worries about the spread of infectious diseases
such as AIDS and hepatitis from the blood supply, blood shortages would not be
as prevalent, there would be no need to specify blood type, and the blood
substitute would hopefully have a longer shelf life than fresh blood. However, a
blood substitute has to possess many of the properties of normal blood. The
blood substitute would have to be able to transport oxygen to various tissues as
needed, and be a large-sized molecule so as not to be removed by the kidneys. 2
It would also have to be stable, easily purified from any contaminants, and nontoxic.
Hemoglobin, which is contained in red blood cells, would seem to be a
natural substitute for blood because it is already present in the human body.
When crosslinked, hemoglobin can also be heated to eliminate any viral
contaminants. 2 Hemoglobin has two main functions within the human body: a) to
deliver oxygen to tissues via the binding of oxygen to the heme iron atoms, and
b) to transport the carbon dioxide byproducts and hydrogen ions from the tissues

2
to the lungs in order to eliminate the carbon dioxide as waste. 3 Therefore,
hemoglobin already functions as an oxygen transporter.
There are various types of hemoglobin which contain combinations of
different subunits. Hemoglobin A discussed in this thesis, is 97.5% of the total
hemoglobin in adult primates. 3 Human hemoglobin A is a tetramer of two alpha
and two beta subunits.

Each of the alpha subunits contains 141 amino acid

residues and each beta subunit has 146 amino residues. 4 Each subunit of
hemoglobin has one heme which consists of a porphyrin ring with one iron atom,
which is the oxygen binding site.
One alpha and one beta subunit interact to form a dimer.

An alpha

subunit has few interactions with the other alpha subunit of a tetramer, and the
same is true for the beta subunits. The major subunit interfaces are a1 ~1,

a2~2,

a1 ~2 and a2~1.

Hemoglobin exists in two conformations: the R (relaxed) state and the T
(tense) state.

In the T state, the hemoglobin is the deoxyhemoglobin or

decreased oxygen binding state. Hemoglobin is a very taut or rigid molecule in
this state due to the formation of eight salt links (electrostatic interactions) as well
as other hydrogen bonds maintaining the deoxyhemoglobin conformation. 3
In order for the transition to the R or oxyhemoglobin state to occur, some
of the salt links and hydrogen bonds must be disrupted. 3 This allows the
hemoglobin molecule to move and the oxygen to bind more easily to the iron
binding site. The binding of oxygen to deoxyhemoglobin is cooperative. 3 After
the first oxygen binds, it then becomes easier for the next oxygen to bind and so
forth. As stated previously, in the transition from the deoxy to oxy state, the
hemoglobin molecule has to change conformation. One dimer, a1 ~1. shifts by 15

3
degrees relative to the other dimer, a2P2, and the

p

chains move closer

together. 3
One problem with the use of hemoglobin as a blood substitute is that in
the oxyhemoglobin form it will dissociate into dimers and be filtered through the
kidneys. One way to solve this problem is to use a crosslinker to stabilize the
tetramers. This crosslinked hemoglobin must then be able to carry out similiar
functions as normal blood, such as transporting oxygen. Thus the search for the
best crosslinker of hemoglobin continues.

History of Hemoglobin Crosslinkers and Allosteric Modifiers
The majority of the published work with crosslinkers has been due to
attempts to solve the problem of sickling caused by Hemoglobin S. 5 - 11 However,
these potential crosslinkers have been tested in both Hemoglobin A and S in
order to determine the sites of reaction.
There are many known types of crosslinkers.

Schiff base adducts, 12

aspirin analogues5 • 6• 11 • 13 -18 and bis-pyridoxal polyphosphates 19 are only some
of the choices. A crosslinker has many possible interaction sites available on
hemoglobin. The areas of specific interest to us are the bisphosphoglycerate
(BPG) binding site and the a99 site in oxyhemoglobin and in deoxyhemoglobin.
Upon binding to the deoxyhemoglobin (T state), BPG 1 bridges the

p

chains, which stabilizes the tetramer in the T state and decreases the oxygen
affinity. In oxyhemoglobin (R state), the proximity of the

p subunits

forces the

BPG out of the binding pocket. Thus, BPG is acting as an allosteric regulator of
both the oxygen binding and the conformation (Tor R) of hemoglobin.

4

BPG

1
Schiff base adducts are one type of monofunctional crosslinker. Zaugg
and coworkers examined 31 carbonyl compounds (Figure 1) which react with an
amino group on the hemoglobin A and S proteins to form reversible Schiff base
compounds. 12

Aromatic aldehydes produced the greatest changes in

intracellular hemoglobin in binding of oxygen compared to aliphatic aldehydes
(less reactive) and ketones (none were reactive). The hemoglobin modified by
aromatic aldehydes resulted in an increase in oxygen affinity compared to the
hemoglobin modified by aliphatic aldehydes and ketones which exhibited no
increase in oxygen affinity.

Aromatic aldehydes were suggested to form

relatively stable bonds in hemoglobin through reaction with an amine of a lysine
residue. Additionally, the addition of a second functional group on the aromatic
ring significantly affected the oxygen binding.

The rate of the Schiff base

formation reaction increased when an electron-withdrawing substituent was
present. Bulky substituents next to the carbonyl prohibited this reaction from
occuring. Compounds were most potent when there was a hydroxyl group in the
ortho position. This was suggested to help guide the ligand to a specific site on
hemoglobin.
Beddell 20 · 21 and coworkers used molecular modeling to propose three
possible compounds that could interact in the BPG binding site of

5

FIGURE 1
31 Schiff Base Adducts Tested as Monofunctional Crosslinkers.
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7
Beddell examined the BPG binding in the X-ray crystal

structure of deoxyhemoglobin. 22 Eight nitrogens in the BPG site were further
examined: two from the terminal amino groups of the
Lys P82, and His P143 from each

p subunit.

p chains,

and from His

p2,

A desired characteristic of a ligand

was a lower polarity than BPG, allowing the compound to cross the red cell
membrane.

Other desired characteristics were that the molecule be novel,

conformationally limited and easy to synthesize. This molecule was designed to
react at the terminal amino groups of the

p subunits.

The starting ligand was one

proposed by Robertson 23 - a bibenzyl structure. Aldehyde groups were added in
the para positions to enable the molecule to form Schiff bases with the
deoxyhemoglobin. Unfortunately, this molecule was not soluble in water, so the
structure was modified to increase solubility resulting in ligand 2.

2
Other compounds that were suggested included a bisulphite derivative 3
and an analogue 4 which was a combination of compounds 2 and 3.

3

8

CHOH
I

S03H

4
Synthesis and testing of these compounds showed the design was successful
and all the compounds promoted liberation of oxygen from deoxyhemoglobin,
similar to BPG. 3 was even comparable in potency to BPG as measured by the
right shift in the oxygen affinity graph, indicating a decrease in oxygen affinity.
NMR experiments 21 provided support for the proposed mode of interaction of 2
and 3 in the BPG binding site.
Aspirin and diaspirin analogues have long been known to act as potent
acylating agents of the amine groups on hemoglobin. 5 • 6• 11 • 13-18 Aspirin 5 is a
member of the acylsalicylates group and diaspirin, for example 6, is a doubleheaded aspirin with various groups bridging the two aspirin portions.
COOH

5
From these studies much can be learned about the crosslinking sites on
oxyhemoglobin. Acyl groups with 2 or 3 carbons in the chain are more reactive
than those with longer carbon chains of 4 to 1O methylene groups 11 • 13 (see Table
1).

However, the compounds with longer chains permeate the red cell

membrane easier than those with shorter carbon chains. 13 Diaspirins, whether

9

TABLE 1
Percent Crosslinking for Acyl Groups with Varying Carbon Chain Lengths.

%
COO-

Cross-linked~

85
10

R

0
0
0

2

COO-

R

0

-CH=CH-CH 2CH 2-(CH2)s-

0
Br

Br

70
40
0

2

Source:R.H. Zaugg, J.A. Walder, R.Y. Walder, J.M. Steele, and l.M.
Klotz. Modification of Hemoglobin with Analogs of Aspirin. J. Biol. Chem.
255: 2816-2821 (1980).
b

Bridge between aspirin groups

c
% Cross-linked is the percentage of hemoglobin 13 chains that are
crosslinked by various bis(salicyl) diesters

10
Br

0
Br

J

II

H

0

I

II

o-c-c=~-c-o

C=O
I

Br

O=C
I

0-

0-

DBSF

6
brominated or not, are more reactive than monoaspirins. 13 Bromination of the
aromatic ring helps transport the ligand across the membrane. 13 In addition,
since bromine is an electron-withdrawing substituent, nucleophilic attack by a
hemoglobin amine group on the carbonyl group is facilitated. 13 Unsaturated
chains have a higher percentage of crosslinking compared to saturated chains,
which can be attributed to the inductive effect of the olefin which increases the
!ability of the ester. 15
These data explain why bis-(3,5-dibromosalicyl)fumarate (DBSF) 6 is able
to crosslink oxyhemoglobin. DBSF is a diaspirin with a two carbon chain length.
The bromine substituents aid in crossing the cell membrane, and the electronwithdrawing nature of the substituents improves nucleophilic attack on the
carbonyl group. Also, DBSF has an unsaturated chain which increases the rate
of crosslinking.
Polyphosphates 19• 24-26 are another group of crosslinkers which have been
used. The proposed crosslinking site of bis-pyridoxal polyphosphates (Table 2)
is from the N-terminal amine on one beta subunit to the

ps2 lysine on the other p

subunit. 19 · 26 Benesch and coworkers varied the number of phosphate groups
between two pyridoxal rings to determine the effect on crosslinking. 1 9
Surprisingly, the 4 phosphate groups between pyridoxal rings resulted in a

11

TABLE 2
Percent Crosslinking for Bis-pyridoxal Polyphosphate Compounds
CH(=O)
HO

0-

0-

CH(=O)

o-~-R+O
II
0

OH

0

% Tetramera

R
Oxygen

16

Orthophosphate

18

Pyrophosphate

68

Methylene diphosphate

53

Fructose 1,6-diphosphate

41

2 ,3-diphosphog lycerate

70

Source: R.E. Benesch and S. Kwong. Bis-Pyrjdoxal Polyphosphates: A
New Class of Specific lntramolecular Crossljnkjng Agents for
Hemoglobin. Biochem. Biophys. Res. Commun. 156: 9-14 (1988).
a

% Tetramer: Covalent lntramolecular Crosslinking of
Deoxyhemoglobin

by the Bis-Pyridoxal Polyphosphates

12
recovering of 68% of the crosslinked

tetramer. 19

This ligand is clearly much

longer than the 11 A distance observed in the X-ray structure between the Nterminal amine and

~282

lysine. One possible explanation is that the pyridine

rings of the ligand must interact with each other. Thus, hemoglobin crosslinked
with this class of compounds could be considered as a blood substitute since
there is a very high yield of crosslinked tetramer, and experimentally it was
determined to have a low oxygen affinity.
The initial work of Abraham and coworkers was in antisickling agents 7· 8
with later efforts in the allosteric modification of hemoglobin. 9 ·

27 · 28

Many of

these allosteric modifiers are not crosslinking agents, however they do bind at
specific sites in hemoglobin.

Allosteric modifiers affect the preferred

conformation of the hemoglobin molecule in the same way as the biological
allosteric effector molecule, BPG.
The first nonnatural allosteric inhibitor reported by Abraham was clofibric
acid (CFA) 7.7 The binding sites of CFA were determined by both X-ray and
solution-binding studies. 28 CFA binds in deoxyhemoglobin in two primary (high
occupancy) sites, between the a subunits, and two secondary (low occupancy)
sites. The secondary sites are located in the central cavity where the a and
subunits meet.

Cl
CFA

7

~

13

Perutz and Poyart discovered a more potent allosteric inhibitor,
bezafibrate (BZF) 8. 27 BZF occupied one of the primary sites, and also one of
the secondary sites filled by CFA.

Lalezari and coworkers reported that

analogues of BZF, urea derivatives, 9, were even more potent allosteric effectors
than BZF itself. 28

COOH

Cl

Bezafibrate (BZF)

8

a= 3,4-0

b = 3,5 - Cl
c = 3,4,5 - Cl

9
These derivatives were also found to bind in a similar manner as BZF. Abraham
and coworkers then reported on three series of compounds, 10-12, similar in
structure to Perutz's compounds 8 and 9, which also are allosteric effectors. 28 10
and 11 occupy a binding site in the a subunits near lysine 99 of hemoglobin
similar to BZF and the urea derivatives.

14

H

I

R~

v

0

x

COOH

a=4-0
b = 3,5 - Cl
c =3,4,5 - Cl

10

0
N
I

H

a= 4 -Cl
b = 3,5 -Cl
c = 3,4,5 - Cl

o"><:ooH

11

12

Even more recently, mellitic dianhydrides29 13 have been shown to
crosslink deoxyhemoglobin.

These compounds decrease oxygen affinity,

maintain much of the cooperativity of binding and reduce the Bohr effect.
Interestingly, these compounds are believed to crosslink deoxyhemoglobin in the
cx.99 site because of the results of competition experiments with known
crosslinkers.

15
0

0

0

13

Goal of This Study
The goal of this research was to use molecular modeling techniques to
develop a molecule that would crosslink hemoglobin upon irradiation. In order to
achieve this goal, the initial research effort was to examine hemoglobin, the sites
where crosslinking is known to occur, and many literature references about
crosslinking hemoglobin. The possible mechanism of crosslinking was explored
using molecular dynamics and minimization experiments. After the simulation of
binding of known crosslinkers, we then used various computer programs to
develop a molecule which is suggested to crosslink deoxyhemoglobin between
the a subunits.

CHAPTER 2
EXAMINATION OF HEMOGLOBIN

Introduction
Our initial goal was to gain familiarity and intuition into the binding and
crosslinking of hemoglobin.

Conformational Search of Djaspirin
The research began with an examination of a known crosslinker in various
sites of the deoxyhemoglobin 22 and oxyhemoglobin 30 X-ray crystal structures
from the Brookhaven Protein Database, 31 2HHB and 1HHO, respectively. The
known crosslinker is bis-(3,5-dibromosalicyl)fumarate, or diaspirin (DBSF), 6,
which crosslinks oxyhemoglobin at the pa2-pa2 residues. 15
The conformation which DBSF adopts to bind to hemoglobin is unknown,
therefore a conformational search was performed.

The molecule was

constructed in Chem-X, 32 and its energy was minimized using molecular
mechanics to remove any steric interactions. One hundred conformations were
generated using a distance geometry program called Dgeom 33 , with the Chem-X
minimized structure as the initial starting structure.
Dgeom describes the structure of a molecule with a distance matrix for
each pair of atoms in the molecule. The program uses a triangle inequality

16

17
algorithm which sets up an upper bounds (maximum distance) and a lower
bounds (lower distance) that is used for each pair of atoms, or distances from the
starting structure. Through the use of this matrix, random conformations are
generated.
These conformations were then submitted to the program Reject. 34 Reject
compares distances between given atoms and based upon this comparison,
duplicate conformations within an allowed tolerance are deleted. The atoms
compared are shown in Figure 2 and the tolerance used was 0.2

A.

Thirteen

conformations were kept, and then minimized to reduce any steric hindrances
using two different programs, Chem-X and Oiscover. 35 The results from the
minimization are given in Table 3, with the energies calculated by both programs.
Both programs minimized the conformations in the gas phase due to the
uncertainty in determining the dielectric constant and the solvent interactions.
Nine out of the thirteen minimized conformations of DBSF, determined by
either the Chem-X or Discover minimization, were a trans conformation (Table 3),
the actual conformation of the reagent. It would seem reasonable that this lowenergy configuration is most likely to occur when binding to the hemoglobin
protein. The differences in the energy values of the minimized conformations
from the two programs are due to the different force fields and parameters used
by each of the programs.

Investigation of Hemoglobin Crosslinking Sites
An exploration of oxy and deoxy hemoglobin was undertaken in an effort
to gain some familiarity with the two conformations of hemoglobin and the sites
where crosslinking either occurs or is thought to occur. Therefore, using one
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FIGURE 2
The DBSF Molecule with Atom Numbers as Used in the Reject
Program

0
DBSF
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TABLE 3
The Relative Minimized Energies of the DBSF Conformations Kept from the
Reject Program.a
Conformationb
dbbfxm87
dbbfxm99
dbbfxm92 (cis)
dbbfxm94
dbbfxm86
dbbfxm61
dbbfxm71
dbbfxm77 (cis)
dbbfxm88 (cis)
dbbfxm98
dbbfxm66
dbbfxm70
dbbfxm91 (cis)

Chem-X (Kcal/mol)
-18.47
-17.60
-15.77
-12.37
-11.62
- 8.01
- 7.90
- 7.74
- 7.66
- 7.09
- 4.96
- 3.84
12.07

Discover (Kcal/mol)
63.95
63.90
60.26
71.09
64.05
67.41
67.92
69.66
66.42
72.60
70.84
66.07
69.70

a

The differences in the numbers between the two programs is due to
the different force fields and parameters used in each program.

b

Unless otherwise specified, trans conformations are listed. The
conformational names refer to the experimental codes.
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conformation of diaspirin, dbbfxm87, and a minimization program, Discover, five
different sites were explored in hemoglobin. This conformation of diaspirin was
chosen because it was the lowest energy conformation calculated by Chem-X.
Diaspirin is known to crosslink oxyhemoglobin between the carbonyl
carbons of diaspirin and the

~-nitrogen

atoms of the lysine residues positions at

13 1a2-13 2a2.1s. 16 This compound is also known to crosslink in the same manner
in deoxyhemoglobin between two lysines at the a99 sites. 36 · 37 There are three
other sites in deoxyhemoglobin, 13182-13282, 13182-132132, 13182-1321, which are
possible secondary sites for crosslinking to occur. 37 All the sites involve two
lysine residues interacting with the fumarate except for the 13182-1321 site; 131 is
the N-terminal valine residue. Thus, the sole oxyhemoglobin site and the four
deoxyhemoglobin sites were explored to elucidate why a crosslinker would bind
in one site versus another.
Using the oxyhemoglobin and deoxyhemoglobin crystal structures, the
fumarate was manually placed in the particular protein site being examined.
Bonds were made between the carbonyl carbon of the fumarate and the nitrogen
atoms of the lysines on both sides of either the alpha or beta chains except for
the 13182-1321 site in which bonds were made to the 1321 valine and the 13182
lysine amine. Since it would be too computationally intensive, and of minimal
utility, to minimize the entire hemoglobin tetramer, only a subset of atoms of the
beta chain or alpha chain within 1O A of the alpha carbon of lysine 1382 or a99
were considered. Atom potentials and charges were assigned by the Insight

38

program. The 1O A subset was minimized in Discover allowing only the fumarate
and lysine chains to move.

The rest of the atoms were held fixed.

The

minimization used the conjugate gradients method 35 until the root mean square
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(RMS) derivatives were less than 0.01. Table 4 lists energies for the minimized
subsets of atoms.

Results and Discussion
Figures 3 to 7 show the minimized structures at the various crosslinking
sites.

The results of the minimization experiments of the different sites

corroborates the experimental results from the crosslinking experiments.
Comparison of Figure 3 (oxyhemoglobin, pl 82-P2 82)

and Figure 4

(deoxyhemoglobin, cq99-a299) to Figures 5-7 (deoxyhemoglobin P182-P282,
P182-P2132 and P182-P21, respectively), shows that the minimized conformations
of the fumarates in the p-cleft of deoxyhemoglobin with p subunits crosslinked
(Figures 5-7) are fully extended and the bond distances are slightly longer than
normal bond lengths. The oxyhemoglobin at P182-P282 and deoxyhemoglobin
al 99-a299 cross links are more relaxed and the conformations are more folded.
From these results we suggest that the secondary crosslinking site in
deoxyhemoglobin is the P182-P282 site. This conclusion was obtained after
consideration of the distance between binding points in each site and when
fumarate is bound, how it is oriented and how stretched the bonds are. The
distance of the deoxy Pl 82-P282 site were closer in length (9.33 A) to the known
crosslinking binding sites of deoxy a199-a299 (7.82

A) and oxy P182-P282 (10.73

A). Also, the energy of the minimized structure of the deoxy Pl 82-P282 site (1.90
Kcal.) was lower then either of the deoxy Pl 82-P21 (35.96 Kcal.) or P1132-P282
(60.05 Kcal.) sites. An argument against the secondary binding site suggestion
is that no crosslinked pa2 in deoxyhemoglobin has ever been isolated.
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FIGURE 3

Minimization of crosslinked oxyhemoglobin:

~182-~282

site.

The distances between each atom of the crosslink are measured.
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FIGURE 4

Minimization of crosslinked deoxyhemoglobin: a199-a299 site.
The distances between each atom of the crosslink are measured.
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FIGURE 5

Minimization of crosslinked deoxyhemoglobin: J3182-J3282 site. The
distances between the atoms of the crosslink are measured.
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FIGURE 6

Minimization of crosslinked deoxyhemoglobin: ~l 82-~2132 site.
The distances between the atoms of the crosslink are measured.
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FIGURE 7

Minimization of crosslinked deoxyhemoglobin:

~182-~21

site.

The distances between the crosslinked atoms are measured.

32
The results of this portion of the research demonstrated why one
molecule, DBSF, crosslinks at these sites.
secondary site.

It also suggested a potential

Thus, this theoretical experimentation verified previous

experimental work and provides insight regarding binding and crosslinking.
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TABLE 4
Energy of Minimized Structure and
Measured Distances of X-ray Structures
FINAL ENERGY OF
MINIMIZED STRUCTURE
(KCAL.)

DISTANCE OF CAMINO
OF ONE LYSINE TO CAMINE OF OTHER
LYSINE (A)*

Oxy: P182-P282
Deoxy: a 199-a299

-39.21

10.73

-78.63

7.82

Deoxy: P182-P282

1.90

9.33

Deoxy: P182-P21

35.96

11.40

Deoxy: P1132-P282

60.05

13.91

*The distances measured are from the X-ray crystal structures from noncrosslinked hemoglobins before any minimizations were completed.

CHAPTER 3
MINIMIZATION OF OXY AND DEOXY HEMOGLOBIN
CROSSLINKED WITH DBSF

Introduction
Chapter 2 discussed the orientation of the DBSF ligand, after crosslinking
both deoxy and oxy hemoglobin at various sites. These calculations allowed only
the fumarate and lysine chains to move during minimization with the remainder of
the protein held fixed.

It would be of interest to examine the crosslinked

hemoglobins after minimization of the entire crosslinked protein and to determine
where changes occurred in the protein.

Methodology
The X-ray crystal structure of deoxyhemoglobin 22 from the Protein Data
Bank31 ,(2HHB) 1.7

A resolution,

was used as the starting structure. DBSF was

manually placed an approximately equal distance (3.32

A and

3.26

~82 lysine side chain amine groups using the lnsight35 program.

A)

from the

Bonds were

made between the ~82 lysines and the ester carbonyls after the 3,5dibromosalicyl rings were removed. The crosslinked protein was then minimized
using the conjugate gradient algorithm in the Discover program for 1O X 100
iterations, holding the mainchain atoms (alpha carbons, carbonyls, and nitrogens)

fixed and allowing only the sidechains to move. Discover also has a method of
34
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restraining, or tethering, the atoms of a protein to their initial coordinates. In
order to minimize major movements of the protein a user-defined force constant,
which controls the strength of the tethering, can be invoked and then decreased
gradually in steps. Therefore, upon completion of this first set of minimizations,
the mainchain was tethered with a force constant of 500 Kcal/A for 1000
minimization iterations. The force constant was decreased to 250 Kcal/A and
another 1000 iterations were performed.

This process was continued with

decreasing force constants of 175, 100, 25, and O Kcal/A with 1000 iterations at
each force constant value. The total computer time was 27 hours on a VAX9000.
The oxyhemoglobin X-ray crystal structure 30 was also minimized with the
DBSF ligand crosslinked at the j382 lysines. The same procedure as described
above was used for deoxyhemoglobin. The cpu time for this minimization was 28
hours on a VAX9000.
A final "control" minimization experiment was to minimize both the native
oxy and deoxyhemoglobin protein exactly as the model crosslinked proteins, as
has previously been described This was performed so that a direct comparison
could be made between the minimized crosslinked protein to the minimized
uncrosslinked native protein.

Results of Minimization
The final crosslinked deoxyhemoglobin structure after minimization was
superimposed upon the original native X-ray crystal structure 8 using the Insight
program. An RMS deviation of 1.18 A was found after superimposing the Calpha atoms. A superposition of all backbone atoms gave an RMS deviation of
1.19

A.

Using the Abbott programs, Histplt and Distplt, 40 ·

41

the distance
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difference for each residue was calculated (Figure 8) and a histogram of the
number of residues which occur at a specified interatomic distance was also
calculated (Figure 9).
The minimized crosslinked and uncrosslinked deoxyhemoglobin proteins
were superimposed upon each other with a carbon alpha RMS deviation of 1.23

A.

The pa2 positions had moved more than most sections of the structure.

However, the largest changes in the minimized crosslinked structure were not at
the pa2 positions. The same plots of the distance difference for each residue
(Figure 10) and the histogram of the number of residues which are at certain
interatomic distances were also calculated (Figure 11) for these two proteins.
The minimized oxyhemoglobin crosslinked structure was superimposed on
the X-ray crystal structure 30 with an RMS deviation of 1.47

A between

all alpha

carbons. There was also a 1.47 Adeviation between all backbone atoms. When
only one a helix of the X-ray structure is compared with the crosslinked
minimized structure, an RMS deviation of only 0.97

A was

measured. This

suggests that the loop region residues have altered the most. The distance
difference for each residue and the number of residues which occur at a specified
interatomic distance were also calculated (Figures 12 and 13 respectively).
The superposition of the minimized pa2 crosslinked oxyhemoglobin with
uncrosslinked minimized oxyhemoglobin was completed with an RMS deviation
of the C-alpha's being 1.36

A.

Figure 14 is the distance difference for each

residue and Figure 15 is a histogram of the occurrence of residues at each
interatomic distance. As in deoxyhemoglobin, the pa2 residues did not show the
greatest movement. Residue (55) of the a chain moved the most.
The RMS deviation measured between the crystal structure and the
minimized crosslinked structure, and also for the minimized crosslinked and
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FIGURE 8

Differences between C-alpha atom positions of
and the X-ray structure of deoxyhemoglobin.

pa2 crosslinked
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FIGURE 9

lnteratomic distances between the C-alphas of the
~82

crosslinked and X-ray structure of deoxyhemoglobin.
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FIGURE 10

Differences between C-alpha atom positions of

~82

and minimized X-ray structure of deoxyhemoglobin.

crosslinked
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FIGURE 11

lnteratomic distances between the C-alphas of the ~82 crosslinked
and minimized X-ray structure of deoxyhemoglobin.
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FIGURE 12

Differences between C-alpha atom positions of J382 crosslinked
and the X-ray structure of oxyhemoglobin.
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FIGURE 13

lnteratomic distances between the C-alphas of the 1382 crosslinked
and X-ray structure of oxyhemoglobin.
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FIGURE 14

Differences between C-alpha atom positions of ~82 crosslinked
and the minimized X-ray structure of oxyhemoglobin.
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FIGURE 15

lnteratomic distances between the C-alphas of the

~82

and the minimized X-ray structure of oxyhemoglobin.

crosslinked
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uncrosslinked proteins, were acceptable for both oxyhemoglobin and
deoxyhemoglobin. 42 A small RMS deviation (for example 0.2 A) would indicate
only a small change has occurred after minimization. However, hemoglobin is
large and has different structural features (a. helicies). 3

These secondary

structure features would be expected to maintain their conformations. The loop
residues between these features would be expected to vary more after
minimization. The minimization did not include solvent interactions which would
aid in holding the loop regions and end residues in a fixed position. We were not
overly concerned that there was some movement of residues, since the RMS
deviation was less than 5.0

A.

Also, the crosslinked deoxyhemoglobin structure

did not minimize to a conformation similar to the oxyhemoglobin X-ray structure.
The RMS deviation of the crosslinked deoxyhemoglobin structure to the X-ray
structure of oxyhemoglobin for the alpha carbons was 2.56

A and

for the

mainchain atoms (carbon alphas, carbonyls, and nitrogens) was also 2.56

A.

Therefore, the deoxyhemoglobin structure did not minimize to the oxyhemoglobin
conformation.
One interesting observation for deoxyhemoglobin is that there was a
greater movement of residues for the crosslinked protein when compared with
the uncrosslinked minimized structure (Figure 10) rather than with the X-ray
structure (Figure 8). This was just the reverse situation for oxyhemoglobin when
Figures 12 and 14 are compared. At present, there is no reasonable explanation
of why there is this difference. The RMS deviations were reasonable for any of
these comparisons. Preliminary X-ray crystallographic results for the deoxy ~82
crosslinked hemoglobin 43 also indicate that this structure is more similar to
normal deoxyhemoglobin than it is to oxyhemoglobin. This is consistent with the
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results presented here. A complete comparison of these two models will be done
when the final X-ray coordinates are available.

CHAPTER 4
MOLECULAR DYNAMICS EXPERIMENTS

lntroductjon
There are a number of groups who have studied hemoglobin using
molecular dynamics experiments. 42 • 44 -48 Michael Johnson and coworkers, 42
along with Martin Karplus and associates, 44 used molecular dynamics to study
the movement of sickle and hemoglobin A in order to compare flexibility of the
two structures. This chapter will describe the molecular dynamics experiments
that were performed to decipher the possible mode of interaction of a crosslinker,
DBSF, with oxyhemoglobin. This mechanism is believed to be typical for many
other crosslinking reactions.

Methodology
A molecular dynamics experiment was utilized in order to investigate the
possible movement of the ligand in the binding site. The programs employed
were lnsight35 and Discover. The DBSF ligand was manually oriented in the
BPG binding site (~ 182-~282) of oxyhemoglobin 30 using the Insight program.
One of the carbonyl carbons of the ligand was bonded to the nitrogen of lysine
~82 as if it had reacted at this site. A subset was created that was 15 A from the

center of the

~82-~82

site. This subset is further subdivided into three volumes
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Afrom the center
~82 oxyhemoglobin site were held rigid, 2) the residues from 13 - 8 A were

when running the molecular dynamics: 1) the residues 15 - 13
of the

tethered (allowed to move slightly but somewhat restrained to their original
position), and 3) the residues within 8

A to

the center were allowed to move

freely. These constraints allowed the ligand and protein within 8

A from

the

center to move and change conformation in order to avoid repulsive contacts and
to simulate motion that occurs when DBSF binds in this site. All hydrogens were
used in the molecular dynamics; the ionizable residues were used in the charge
states seen at pH 7.0. In addition, if creation of this 15

A subset

resulted in

partial residues, the entire residue was included in the subset.
The attached ligand and the side chains that were allowed to move in the
oxyhemoglobin 8

A subset were

minimized for 100 iterations. This was in order

to remove repulsive contacts between the ligand, which had been manually fitted
into the protein, and the protein itself. The temperature of the system was
allowed to adjust to 300 K after 1000 iterations of molecular dynamics
equilibration.

Discover has an algorithm that adjusts temperature by scaling

velocities. If the temperature is far from the temperature set for equilibrium, the
velocities are increased vigorously until the temperature is met. The temperature
was kept constant using another algorithm that varies the temperature slightly, as
if the system were coupled to a heat bath, for the remainder of the dynamics
calculations. The molecular dynamics experiment used the Verlet algorithm. 35
The initial experiment was set up so that the dynamics ran for 1000 iterations
using a time step of 1 femtosecond, for a total of 1 picosecond. Every tenth
iteration was written out to a file which was later loaded into the Insight program
to make a movie for a visual depiction of the atom movements.
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Modifications on thjs Experiment
The initial dynamics experiment was modified several times in order to
address specific mechanistic and procedural questions. In the first modification,
the temperature was gradually increased by 20° increments from the initial
temperature of O K, and allowed to run for 100 iterations after each increment
until a temperature of 300 K was reached. The 1000 iterations of molecular
dynamics then followed this gradual equilibration. This experiment determined
whether there would be a change in the motion and distance of the lysine

~82

to

the attached ligand if the temperature was gradually equilibrated or set at a
specific temperature.
In a second modification the charge on the

~82

lysine amino group that

was interacting with the bound DBSF ligand was varied. In the initial experiment,
the lysine amine was positively charged while the acid substituent on the ligand
was negatively charged, simulating a physiological pH of 7.0. Therefore, the
charged species would be attracted toward each other.

In a separate

experiment, the lysine residue on the protein was deprotonated so it has a
neutral charge and the molecular dynamics experiment was recalculated.
Another modification to the molecular dynamics experiment lengthened
the number of iterations from 1,000 to 100,000 with both the charged and neutral
ligands bound to one

~82

lysine. Every 1OOth iteration was written to a file for

each run. This experiment explored the frequency of the bound ligand coming in
close contact with the crosslinking

~82

lysine.

The last modification to this experiment changed the subset specification
on the charged lysine experiment in order to determine whether a larger subset
of moving residues would result in a different answer. A new subset was created
to give a 25

A size, which

was further subdivided into three volumes. The three
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volumes were: 1) 25 - 16
16 - 13

A were tethered,

Afrom

the center was held rigid, 2) the residues from

and 3) 13

A to the center was allowed to

move freely.

This experiment gave a 5 A radial increase to the volume of residues which were
allowed to move freely rather than being tethered, compared to the initial
experiment.

Results
The molecular dynamics experiments with DBSF bound to one side of
oxyhemoglobin (1382) enables one to determine how the bound ligand could
interact with the lysine j382 of the other subunit. The results of the experiment
between the gradually equilibrated dynamics run versus a rapidly equilibrated
system showed that the gradually equilibrated run allowed the bound ligand to
interact more closely (Figure 16) with the j382 lysine than the fixed temperature
equilibration (Figure 17). The gradual equilibration allows a better resolution of
problems caused by bad contacts between the reagent and the protein and is
probably a truer measure of the physiological state of the protein-ligand
interactions. Therefore, all further molecular dynamics experiments were allowed
to attain the equilibration temperature gradually, even at the expense of
increased computer time. The computer time for the calculation increased on
going from the fixed temperature regime (8 hours 52 minutes) to the slowly
equilibrated system (11 hours 28 minutes) on a VAX 9000 computer.
The second modification, which varied the charge on the j382 lysine amino
group interacting with the DBSF ligand bound to the other j382 residue, showed
that the charged species were attracted toward each other. The two groups that

would make the crosslink are the charged lysine
carbonyl.

~82

amino group and the ester

The nearest distance between these groups was close
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FIGURE 16
Molecular dynamics with gradually equilibrated temperature of bound
DBSF on oxyhemoglobin. After each 200 increment, 100 iterations of
dynamics were performed until reaching 300 K.

1,000 iterations of

molecular dynamics followed the gradual equilibration. The distance
measured is between the bound ligand and the ~82 lysine on the other
subunit.
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FIGURE 17

Molecular dynamics at fixed temperature of bound DBSF on
oxyhemoglobin.

The temperature was set at 3000 and 1,000

iterations of molecular dynamics were performed.
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enough (3.5

A) 49

between3.5 - 6.0

A.

for the crosslinking to occur.

The distance averaged

It appears that the carboxylate on the aromatic ring attracts

the lysine J382 and brings it sufficiently close for the crosslinking to occur (Figure
16).
This experiment was run three times and the closest contact between the
neutral lysine J382 and the ester carbonyl was 4.11

A.

This is too great a distance

for a crosslinking to occur (Figure 18). 49 Therefore, if the mechanism for
crosslinking begins when one J382 lysine reacts with one ester carbonyl of DBSF,
the negatively charged carboxylate group on the DBSF could aid the crosslinking
with the other J382 lysine, by increasing the probability that the two reacting
groups will be sufficiently close for reaction. It should be noted that the NH3+
lysine must still deprotonate prior to making the new bond.
The third modification lengthened the number of molecular dynamics
iterations from 1,000 to 100,000 with experiments for both the charged and
neutral lysine J382.

In the 100,000 iteration experiment, the neutral ligand

averaged a distance of between 12 - 16

Abetween the

carbonyl. The closest approach was approximately 5.5

J382 lysine and the ester

A between the ligand and

the lysine (Figure 19). The distance between the carbonyl and the charged
lysine in the 100,000 iteration experiment averaged a distance of 5.0 - 6.5
(Figure 20) with the closest contact being 4.8

A.

A

The negatively charged ligand

was attracted to the positively charged lysine as evidenced by the shorter
distance of interaction. This result revealed that this interaction could occur
frequently if this is the mechanism for crosslinking. It should be emphasized that
both the short and longer molecular dynamics experiments agreed there is a
greater possibility for the charged lysine to interact with the negatively charged
ligand than the neutral lysine amine.
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FIGURE 18

Molecular dynamics for 1,000 Iterations: Measuring the distance
between the neutral
of bound DBSF.
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FIGURE 19

Molecular dynamics for 100,000 iterations: Measuring the distance
between the neutral
bound DBSF.
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FIGURE 20

Molecular dynamics for 100,000 iterations: Measuring the distance
between the protonated

pa2 lysine nitrogen and the salicylic acid.
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At this time, it can not be explained why there is a variation in the
distances of interaction when comparing the shorter molecular dynamics runs
and the longer one. One possible way to resolve this would be to write the
molecular dynamics coordinates to a file more frequently than every 100
iterations. However, this was not done because the trajectory file where the
coordinates were sampled every 100 iterations was already very large.
In the last modification, the subset of atoms considered in the molecular
dynamics experiments with a charged lysine was increased from 15

A to

25

A.

We originally intended to perform 100,000 iterations, but unfortunately the VAX
9000 crashed after about 40,000 iterations and the program was restarted for
another 60,000 iterations. Thus the total iterations is 100,000 but the results will
be shown in two parts: part a is the 40,000 iteration piece and part b is the
60,000 iteration portion of the trajectory. The closest approach between the
lysine amine and the ester carbonyl was 4.19

A for part a (Figure 21) and 3.91 A

for part b (Figure 23). The interesting result is that the distance from the lysine
amine to the acid oxygen on the dibromosalicyl part was only 2.5

A for both part

a and b (Figures 22,24).
The mechanism of crosslinking is thought to occur in a two step
mechanism: 1) one side of DBSF reacts with one
and then, 2) the other

~82

~82

lysine of oxyhemoglobin

lysine comes in close contact due to electrostatic

interactions with the acid to complete the crosslink. However, at pH 7.0, the
lysine would be charged and only the uncharged species would attack the
carbonyl of the substrate. Therefore, we speculate that the carboxylate of the
salicylate leaving group not only electrostatically attracts and orients the reactive
lysine, but also deprotonates the

~-amino

group, making it a better nucleophile.

Both of these factors would increase the specificity and the speed of the

crosslinking reaction.
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FIGURE 21

Molecular dynamics for 40,000 iterations: Subset size is 25
measuring the distance between the protonated
and ester carbonyl of bound DBSF.
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FIGURE 22

Molecular dynamics for 40,000 iterations: Subset size is 25
measuring the distance between the protonated
and the salicylic acid.
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FIGURE 23

Molecular dynamics for 60,000 iterations: Subset size is 25

A

measuring the distance between the protonated 1382 lysine nitrogen
and ester carbonyl of bound DBSF.

09
Qfl

0£

oz

(sd)aUI1J,

01

0

77

78

FIGURE 24

Molecular dynamics for 60,000 iterations: Subset size is 25
measuring the distance between the protonated
and the salicylic acid.
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CHAPTER 5
THE DEVELOPMENT OF A PHOTOAFFINITY
CROSSLINKER FOR HEMOGLOBIN

Introduction
The purpose of this portion of research was to design a molecule using
molecular modeling techniques that would crosslink hemoglobin when irradiated
by light. Chapters 1-4 described the characterization of the different crosslinking
sites in hemoglobin and the possible mode of interaction.

This chapter will

describe the process involved in the development of a new crosslinker.

There were several problems which needed to be addressed in order to
develop a new crosslinker. The first problem was to find a computer program
that could reproduce the binding of a known ligand in either deoxy or
oxyhemoglobin. Abraham and associates examined the binding of bezafibrate
and its analogues 8,10-12 28 in the a99 site of deoxyhemoglobin. This paper
included a description of the ligand binding sites and mentioned that the X-ray
coordinates were available from the authors. We obtained one set of coordinates
for 3,5-dimethoxybezafibrate, 14, from Abraham in the Protein Data Bank format
(PDB coordinates: protein plus ligands bound). A second set of coordinates of
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the bezafibrate analogues 8,10,11 mentioned in this article were obtained at a
later date in PDB format.

N

I

H

14
These coordinates were converted into an ASCII file, which was subsequently
converted into PDB format using Chem-X so that it could be read into Insight.
Our intention was to take a conformation of one of the bezafibrate analogues,
and using the Dock program 50 -52 to reproduce the position of the ligand in the
a99 deoxyhemoglobin site.
In order to use the Dock program, several steps must be completed before
the ligand can be docked into the protein site. Initially, the program Sphgen 50 -52
generates clusters of spheres which characterize the receptor site. A second
program, Distmap 50 -52 or Chemgrid, 50 -52 creates a grid of the receptor site so
that a score could be calculated for the fit of the ligand within the receptor, using
either contact or forcefield scoring. In the next step, the ligand is placed into the
receptor site, and the fit evaluated based on either 1) contact or surface
interactions, 2) contact scoring with Delphi electrostatic scoring, 3) force-field
scoring (considers both steric and electrostatic interactions), or 4) a combination
of contact and forcefield scoring.
The protein coordinates, a site region (a subset of the protein) where the
ligand may interact, and the ligand coordinates are used as input to the program.
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The sizes for the regions chosen are either based upon the atoms the program
could accommodate (the protein specification) or the region that best describes
the interaction site of the ligand with the protein (the site subset). A larger site
region increases the computer time, and also places spheres in regions where a
ligand could not be accommodated, for example, on the outside of the protein.
The PDB coordinates used were those supplied by Abraham for 14. All
the waters and the heme groups were removed from the deoxyhemoglobin
protein. The whole protein could not be used since the Dock program has a limit
of 3,000 atoms. Therefore, a region of 25

A from where one of the ligands binds,

containing 2,653 atoms (Figure 25) was used as the protein. The site subset, the
region where the ligand is to be docked, contains the atoms within 15

A from

where the ligand was found to bind (Figure 25). Charges were placed on the
ligand, 14, and written as a Sybyl mol2 file 53 (a file type which contains charges
on the atoms to be used in docking the ligand) using the conformation as found in
the X-ray coordinates. The ligand was moved away from the site where it was
found to bind so as not to bias the results. The protein, subset and ligand were
input into the Dock program and the binding orientations found were scored using
both the contact and the forcefield method.
The same procedure was followed for compound 1Ob and for DBSF 6 in
oxyhemoglobin but using only the forcefield method of scoring.

Results of the Docking Procedure
The dock procedure of the 3,5-dimethoxybezafibrate 14 analogue using
contact scoring placed the ligand in the active site of the protein. The ligand fit

into the open volume of the active site, however, the hydrogen bond interactions
were not taken into account.

83

FIGURE 25

Region used in the Dock program: 25

A for the protein,

where BZF was found in Deoxyhemoglobin. The 25
colored blue. The 15 A subset is colored brown.

15

A subset

A subset

is
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The dock run of 3,5-dimethoxybezafibrate 14 using the forcefield scoring
method showed very promising results, when compared to the PDB coordinates
sent to us by Abrahams. The forcefield energies ranged from -33.0 kcal/mol to
224.0 kcal/mol with -33.0 kcal/mol energy being the best fit of the ligand in the
site. There were over 1000 possible solutions in this site with energies between
-33.0 and -22.0 kcal/mol. The range of solutions considered was then narrowed
to be from -33.0 to -27.0 kcal/mol, and only the best sixty solutions were
examined. Overall, the ligand docked within the same vicinity as found in the Xray structure and in some cases the solutions made better interactions with the
protein than the position of the bound ligand observed in the crystal structure
(Figures 26-27). The position of the ligand in the X-ray structure is questionable
since the lysine of the protein extends through the phenyl ring of the ligand.
One problem with the dock results mentioned above was that the docking
orientation of the molecule was rotated by 180 degrees compared to the X-ray
structure 28 (Figures 26-27). However, since only Van der Waals and electrostatic
interactions of the ligand and protein are used in the scoring value and this does
not include the effects due to water, solvent and other influences, this method
appeared to validate the simulation of a ligand bound in a protein. It is possible
that the orientation of the ligand found in the X-ray structure could be in the
higher energy solutions which were not examined, since many solutions were
found for a small range (recall over 1,000 solutions for the range of -33.0 to -22.0
kcal/mol).

The forcefield scoring method can only approximate the true

interactions.
It should be mentioned that the a99 site being examined has a C2
symmetry axis in which Abraham 28 found a ligand bound in both halves of the
protein. The Dock program gave a result in which a ligand was found to fit in
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FIGURE 26

Dock of dimethoxy compound 14: X-ray structure versus the
docked structure in a99 site of deoxyhemoglobin.

The X-ray

structure is colored red and the docked molecule is colored blue in
the figure.
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FIGURE 27

Dock of dimethoxy compound 14: X-ray structure versus the
docked structure which is in a better position in the a99 site of
deoxyhemoglobin.

The X-ray structure is colored red and the

docked molecule is colored blue.

The distance was measured

between the lysine nitrogen and either the methoxy oxygen in the
X-ray structure (1.28 A) or the ether oxygen in the docked molecule
(3.84A).
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either half of the protein site around the a99 lysine. The program does not have
the capability of placing two ligands in the site at the same time.

So it was

gratifying to find both possibilities present in the 60 solutions that were examined.
The

docking

of

3,5-dichlorobezafibrate

analogue

10b

into

deoxyhemoglobin was also completed using the conformation of the ligand seen
in the X-ray structure. 28

The forcefield energy scores ranged from -32.87

kcal/mo! to greater than 245 .91 kcal/mol. Only the orientations with energy from
-32.87 to -29.00 kcal/mo! were examined. These docking results were better
than the previous docking of 3,5-dimethoxybezafibrate since these results
showed the correct orientation, some solutions were even superimposed on the
X-ray crystal structure of the ligand (Figure 28). As before, the ligand was placed
in both halves of the protein as was found in the X-ray crystal structure. This
further validated use of the Dock program in order to find the placement of a
ligand in a chosen site.
A third docking experiment used the DBSF ligand and examined its
possible binding orientations within deoxyhemoglobin. Since the conformation in
which DBSF binds in the protein is unknown, 100 conformations were generated
in Dgeom and minimized within Chem-X. All 100 minimized structures were
loaded into a Sybyl database and Gasteiger-Huckel charges5 4. 55 were placed on
each conformation. The entire database of conformations with charges were
written out as a mol2 file and converted into a database. This database was then
specified for use in the Dock program.

The Dock program took each

conformation in this database and found the best fit within the specified protein
site. The results indicated that many conformations were placed in the area
where the crosslinking is known to occur experimentally (Figure 29). This was
the first docking experiment in which the conformation of the ligand was
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FIGURE 28

Superposition of the X-ray structure versus the docking of 3,5dichlorobezafibrate 10b in the a99 site of deoxyhemoglobin. The
X-ray structure is colored pink and the docked molecule is colored
orange.
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unknown, and thus gave very encouraging results showing that the program
would place the ligand where crosslink could occur. This is further validation that
this program would give a good idea of the location that a molecule is likely to
bind and could then crosslink within the site.

De Novo Design
Grid
There are a few commercial programs that can help in designing new
compounds for binding when the protein structure is known.

One of these

programs, Grid, 56 was the first "de novo" program explored in this research for
deoxyhemoglobin in the a99 site.
Grid is a program designed to calculate energetically favorable sites in a
protein depending on the specific probe used. 56 Grid employs the Lennard-Jones
potential 56 in which there is a certain distance that gives the most favorable
interaction between two non-bonded atoms. A probe representing a molecule or
particular property (for example a methyl group probes steric regions) is then
moved throughout the protein.

The potential energy, Exyz, of the probe

iscalculated at the array of "grid points" that have been established throughout
the protein.
The protein we used is the subset of deoxyhemoglobin obtained from
Abrahams (which is the same as the X-ray crystal structure), 28 but only half of the
a99 site was used since there is a C2 symmetry axis at the site. The water

molecules and heme groups were removed from the protein. The probes used in
these calculations were the water, hydroxyl, methyl, carboxy, and protonated
amine probes.

An array of energy values were calculated with each of the
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FIGURE 29

Docking of DBSF into the deoxyhemoglobin a99 site. DBSF is the
red colored molecule.
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probes and the energy values visualized using isoenergetic contours in Insight.

Results from Grid
The contours using each of the probes were examined and the range of
energies listed for each probe (Table 5). These contours are very helpful in
designing a new crosslinker for deoxyhemoglobin at the a99 site since it gives
some indication where a bulky group (Me probe) may prefer to be or not be, or
where some electronegative atom may be favorably placed, based upon the Xray crystal structure of deoxyhemoglobin. 22 The contours for each of the probes
are shown in Figures 30-34.

Database Docking
This is similar to the Docking method described previously. The Dock
program searches a database of various structures, rather than using a database
of one molecule with many conformations to be fit into the protein site, and ranks
the compounds based on the scoring method chosen.
The protein was the portion of the a99 deoxyhemoglobin tetramer
encompassing the atoms within 25

Afrom the center of the site.

The database

initially searched was a small database of 200 compounds from the Cambridge
Crystal Database of small molecule X-ray structures. This database allowed for
a search using only the contact scoring method. Another database was created
from the Available Chemicals Database ( ACD, 2,000 compounds) 57 in which
forcefield interactions were searched. The Gasteiger-Huckel charges had been
calculated for these compounds.

TABLE 5
The Range of Energies for Each of the Probes Employed in the Grid Program.

Probe

Range of Energy (Kcal.)

H20

- 9.69 to 5.00

OH-

- 8.54 to 5.00

CH3

- 4.29 to 5.00

coo-

-19.29 to 5.00

NH3+

-25.26 to 5.00
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FIGURE 30

Contour from Grid for the water probe. The red contour are places
in the a99 deoxyhemoglobin site where water or a hydrophilic group
would like to be placed. The energy range for this probe is from
-9.7 to 5.0 Kcal. and these contours are at -6.5 Kcal..
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FIGURE 31

Contours from Grid for the methyl probe. The blue contours are
where a methyl or hydrophobic group would like to be placed. The
energy range for this probe is from -4.3 to 5.0 Kcal. and these
contours are at -3.0 Kcal..
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FIGURE 32

Contours from Grid for the carboxylate probe.

The magenta

contours are where a carboxylate group would like to be placed.
The energy range for this probe is from -19.3 to 5.0 Kcal. and these
contours are at -10.0 Kcal..
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FIGURE 33

Contours from Grid for the hydroxyl probe. The orange contours
are where a hydroxyl group would like to be placed. The energy
range for this probe is from -8.5 to 5.0 Kcal. and these contours are
at -6.0 Kcal..
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FIGURE 34

Contours from Grid for the amine probe. The black contours are
where an amine group would like to be placed. The energy range
for this probe is from -25.3 to 5.0 Kcal. and these contours are at
-15.0 Kcal..
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Results of Database Docking
Using contact or forcefield scoring, the Dock program placed a number of
molecules in the a99 deoxyhemoglobin site. Most molecules were not of interest
since they were too large in size or very toxic. Two molecules that were of
interest are 15 and 16, both of which came from the ACD database, are shown
below. 16 was thought to be too large to fit into the site of interaction, however it
suggested a molecule 17 similar to the diaspirin molecule with the ester
orientation reversed compared to DBSF. One potential problem with 17 is the
possible stability of the molecule - would it react before it reaches the desired

15

OH

0
0
OH
16

109

crosslinking site? Despite this potential problem, 17 was Docked into the a99
deoxyhemoglobin site.

0

/'vo
0
17

Azide groups were added in either the meta and para positions on both of the
phenyl rings, thus creating two molecules to be examined, 18 and 19. 150
conformations were generated with Dgeom for each of 18 and 19. We attempted
to minimize these conformations with Chem-X. However, the azide group could
not be minimized in Chem-X because there were no parameters available,
therefore, an isocyanate (NCO) was substituted in its place, and all
conformations were minimized.

The conformations with the isocyanate

substituent were loaded into Sybyl and Gasteiger-Huckel charges were placed on
each conformation. These conformations for each molecule were written out into
a mol2 file and then converted into a file that was converted to a Dock database.
The Dock program was run for both molecules.

0

18
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Both Dock runs found a small number of conformations of the ligand which
might interact in the a99 site of deoxyhemoglobin. But overall, it didn't seem that
either molecule would have a driving force which would help to direct these
molecules into the a99 site or keep it at that site. Therefore, these molecules
were not pursued any further.

Lu di
Ludi 58 • 59 is a program, incorporated into Insight, which is designed for use
in de novo design of new ligands for a protein. There are three steps in using
Ludi: (1) calculation of interaction sites within the area of the protein that is
chosen to be the binding site, (2) a search in the fragment library for pieces that
will fit the protein site and (3) attaching or linking these fragments to form a new
ligand. Each of these steps will be described in more detail.
The polar atoms of the protein can form favorable hydrogen-bonds from
acceptors and donors positioned within a small area near each of these polar
atoms. The possible locations of these acceptors and donors within these areas
are the interaction sites. The X-ray crystal structure for small molecules revealed
that there was not just one specific point for hydrogen bonding to occur, but
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rather a range of interaction points. There are four types of interaction sites that
are created by Ludi: (1) H-donor, (2) H-acceptor, (3) lipophilic-aliphatic and (4)
lipophilic-aromatic. Hydrogen bond interactions are represented by the H-donor
and acceptor, while hydrophobic interactions are represented by the remaining
two types of interactions.
The second step in this process is fragment fitting. Ludi contains a library
of fragments through which it searches to find those that can interact at the
interaction sites.

The fragments are chosen based upon the square of the

distances between the atoms of the fragments and the interaction sites. 60 Once
a fragment meets these criteria, Ludi performs a root mean square superposition
using the Kabsch algorithm. 60 A fragment is acceptable when the RMS value is
within user specifications (usually 0.2

A to

0.6

A).

Ludi also ensures that there

are no steric or repulsive electrostatic interactions between the fragment and the
protein. Once the fragment has passed these requirements, the coordinates are
then stored in PDB format to be recalled later.
The final step in this procedure is the linking of the accepted fragments
together or onto an already existing molecule. Ludi can position a fragment onto
a hydrogen of the core fragment in an orientation that would be favorable for a
bond to be made. A modified version of Ludi called Autobuild 61 can pick one
acceptable fragment at random and make a bond. The number of fragments to
be attached can be specified, varying from one to three. The program is iterative;
a fragment can be added or built on to a ligand and the process repeated.

Ludi and Dock Experimentation
A subset of the deoxyhemoglobin protein was used in the Ludi run. The
a99 region was of interest, therefore a subset of the protein, 20

A from one of the
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a.99 lysine nitrogens, was created. Ludi searched within a radius of 12
this same a.99 lysine atom.

Fragments with an RMS of 0.3

A or

A from

less were

accepted. The search produced 89 possible fragments that fit within this area.
Two fragments, 20 and 21, were of interest because multiple hydrogen bonds
were made with the protein.

H

I

N+-H

---<

N-H

I

H
20

21

20 made hydrogen bonds to aspartate C126 and tyrosine 035 and 21 had
hydrogen bonds to glutamate 0101 or aspartate 094. These fragments were
then connected by a methylene group creating 22 and the molecule was
minimized to remove any steric repulsions within the a.99 site. 200 conformations
of the bisamidine, 22, were generated with Ogeom and minimized in Chem-X. All

N-H

,.....N+

H

\

I

H

H

22

113

200 conformations were added to a Sybyl database and Gasteiger-Huckel
charges were calculated for each conformation. These were all written into a
mol2 file and converted into a Dock database. A Dock run was then submitted
where the bisamidine database was used to place the molecule in the protein
binding site.
The results of this Dock run were very encouraging since most of the
conformations were placed into the a99 site making many of the hydrogen bonds
bisamidine so that photochemically-induced crosslinking would occur. After
reviewing the literature, 62 -65 it was decided that an aryl azide would be a good
candidate. The aryl azide was added onto the ligand along with a methyl group
which was to represent a second crosslinking portion to be added later to the
bisamidine 23. Gasteiger-Huckel charges were assigned to the ligand. Insight
could not assign charges to the azide group. With the help of Dr. Tetsuro Oie,
appropriate charges for an aryl azide were devised as shown on 24.

H

n = 1 or 2 methylenes

23
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FIGURE 35

Dock of bisamide portion into the deoxyhemoglobin a99 site. The
ligand is forming hydrogen bonds to the aspartic acid (2.05

A)

on

one side and an aspartic acid (1.69 A) and tyrosine residue (1.81 A)
on the other side.

115

116

Charges on the nitrogens are as follows: N 1 = -0.213, N2 = 0.091, and N3 = -0.036.

24

Unfortunately, when 23 was minimized to remove any steric interactions
due to the addition of the aryl azide, Discover was unable to handle the azide
group because of missing parameters. Therefore an amine group replaced the
azide group on the phenyl and was minimized without problem.

200

conformations of each of these two structures (n=1,2) 25 and 26 respectively,
were generated for each molecule by Dgeom with the amine group replacing the
azide group. These conformations were minimized in Chem-X and loaded into a
H
H

25

26
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Sybyl database where Gasteiger-Huckel charges were added.

The

conformations were written out into two separate mol2 files and converted into
files that could be read by Insight. The Dock program was used to determine
whether the compounds would fit into the cx.99 site.
The results from these Dock runs showed that a number of conformations
were placed in the cx.99 site. The major difference between 25 and 26 was that
the molecule with n=2 (26) extended out of the pocket. Therefore, further work
continued with compound 25.
In order to examine whether this is the optimum placement of the azide,
and amidine groups around the phenyl, seven other related ligands were
examined (Figure 36). Each of these seven molecules had 200 conformations
generated in Dgeom and minimized in Chem-X. All the conformations were input
into a Sybyl database and Gasteiger-Huckel charges were placed on each
molecule. The conformations were output into a mol2 file and converted into a
Dock database.
A Dock run was completed for each of the seven compounds.

The

outcome was different for each of 27-33. The best Dock results were from 30.
Dock placed this ligand several times in the cx.99 site of deoxyhemoglobin, and
made two to three hydrogen bonds with the residues within the site. This result is
particularly encouraging since an attraction of the ligand to the binding site
suggests that this ligand will be more likely to be in the active site where the
photoactivated crosslink could occur.

Compounds 27 and 31 also gave

interesting results. Each had some conformations that were placed in the cx.99
site and making one to three hydrogen bonds, although not as many as
compound 30. Nevertheless, they would also be interesting molecules to pursue.

32 and 33 did dock in the vicinity of cx.99, but very often were docked sideways or
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FIGURE 36

7 substituted bisamidines docked into the deoxyhemoglobin a99 site.
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Figure 36
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backward with the aryl azide group in toward the center of the cavity rather than
rotated 1800. 27 and 28 had some well-placed conformations but they were not
making the desired hydrogen bonding interactions.
The last step of the de novo design was to take a conformation of 30 and
add the dibromosalicyl portion to form the new crosslinker 34. In order to obtain
Br

coo-

34
the best assurance that 34 would bind in the a99 deoxyhemoglobin site, 200
conformations were generated and minimized using Dgeom and Chem-X
respectively, with an amine group in place of the azide for the minimization.
These conformations were loaded into a Sybyl database and the amine group
was changed to an azide group. For each of these 200 conformations, the azide
group was rotated 1800 and this conformation was also stored in the database.
Therefore, the database contained 400 conformations of the ligand. GasteigerHuckel charges were assigned for the atoms of each conformation and all
conformations were written into a mol2 file. This mol2 file was converted into a
Dock database and Dock was run.
There were some interesting results in which ligand 34 was oriented in the
protein site as had been designed (Figure 37).

But there were many

conformations in which the ligand was oriented reversing the positions of
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FIGURE 37

Docking of proposed molecule 34 into the a99 deoxyhemoglobin
site.
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the azide and the salicyl groups. This could be due to the size of the salicyl
portion negatively interacting with the a99 lysine side chains. Therefore, two
things were modified: first the mono aspirin was replaced with a phosphate group
and the procedure repeated with this compound. And secondly, since the lysine
sidechains can move and we are dealing with a rigid protein site, the a99 lysine
chains were removed and Dock was repeated using the same database of
compound 34.
The Dock results of the phosphate-substituted ligand showed that almost
all the conformations were oriented very differently from what was desired.
These results again may be due to the bulk of the phosphate group interacting
with the a99 lysine sidechains. There was no difference in the Dock results of
placing the conformations of 34 into a modified protein where an alanine residue
replaced the lysine residue. There were still conformations that fit the site and
made the appropriate hydrogen bonds. But many of the molecules were oriented
with the azide and the salicyl in reverse positions. This is still a promising ligand
because it was placed into the site at least occasionally making the correct
hydrogen bonds and the azide and salicyl ring was placed in the correct
positions.

Results and Discussion
The bisamidine compound, 34, is a good choice for a novel photoaffinity
crosslinker. The amidine portion should form hydrogen bonds with the carboxylic
acid sidechains of residues aspartic acid C126, D94 or glutamic acid D101 in the
binding site. These interactions would help not only to direct the ligand into the
site, but also to keep the ligand in this pocket. The mono-aspirin portion should
crosslink with an a99 lysine residue. Then, with irradiation, the ligand should
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crosslink with the residues near by. This crosslinker has the unique combination
of two different methods of forming covalent bonds between the ligand and the
protein. This molecule, which has been designed to interact specifically with one
site of hemoglobin, represents an attempt to use the methods of molecular
modeling to suggest new compounds to help develop a better blood substitute.

Proposed Synthesis
Figure 38 depicts a proposed synthesis for the photoaffinity crosslinker 34.
The strategy for the synthesis of the bisamidine is to introduce the most reactive
functionality, the phenyl ester, last. The amidine groups are introduced as late as
possible.
The synthesis begins by reaction of the bisester 35 with one equivalent of
sodamide in order to prepare only the monoamide 36. The benzyl alcohol is
oxidized to the carboxylic acid 37 by acidic chromium trioxidess. Treatment with
Meerwein's reagents? (Me30BF 4) will both form the ester and the methyl imidate
from the amide on 37. Treatment with base will form the nitrile on 37. The ester
is then opened with sodium cyanide on 38. The acid is then converted to the
acid chloride and this is used in a Friedel-Crafts68 reaction with nitrobenzene to
form 39. The ketone from the product is deoxygenated by treatment with P4S1 o
and then Raney nickel to form 40. The nitro group is then converted to the
diazonium group, using nitrous acid, which is then converted to the aryl azide by
treatment with sodium azide forming 41.

The ester is then hydrolyzed with

lithium hydroxide to the acid forming 42. This is done to prevent formation of the
amide in the next series of reactions. The nitriles are then converted to the
amidines by any one of many techniques, such as treatment with carbon disulfide
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and ammonia to give compound 42. The remaining task is to form the phenyl
ester

from

dibromosalicylic

acid

and

the

benzoic

acid

using

dicyclohexylcarbodiimide and dimethylaminepyridine as catalyst forming 43. The
salicylic acid may need prior protection as the tert-butyl ester. Treatment with
hydrochloric acid should cleave the acid-sensitive t-butyl ester and form the
bisamide dihyrochloride 43.
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FIGURE 38
Proposed Synthesis of Photoaffinity Crosslinker 34

127
I. Cr03, H+

2.Me30BF4
3. Base

36

CN

~C02Me

NaCN

l.SOC12
AlC13,
2. -nitrobe
- -nzene

H0 C ) U N
C

2

38

CN
CN

HNOifNaN 3

2· Raney Nickel

~

N3
02N

40

~c~'

+H2
I. LiOH

NH 2

2. CS 2
3.NH3

0

Br
0

NH 2

DCC/DMAP

2. HCl

N3

42

f_'\

+H2

Br

I.

-Q"'

41 H02C

N3

43

CHAPTER 6
CONCLUSION

Chapter 2 examined the binding of a crosslinker, DBSF, at the active site
of hemoglobin. A complete conformational search and minimization of DBSF
was completed in order to better understand the types of conformations this
molecule can achieve.

Secondly, the sites where crosslinking is known, or

thought to occur, in both deoxy and oxyhemoglobin were examined using
minimization experiments of DBSF bound within the active sites of these
proteins. In these minimization experiments, only the bound DBSF was allowed
to move. It was through these experiments that an understanding was achieved
of why crosslinking occurs at the P182-P282 site of oxyhemoglobin and the a199a299 site of deoxyhemoglobin. It was also concluded that the P182-P282 site in

deoxyhemoglobin may be the secondary crosslinking site.
Another experiment involved the minimization of the whole protein of both
oxy and deoxyhemoglobin while crosslinked with DBSF.

This experiment

allowed the sidechain residues of the protein to move together with the bound
DBSF. The results of this experiment showed that the a helices do not change
greatly, however the loop regions change significantly. This is consistent with
preliminary X-ray crystallographic results on deoxy P82 crosslinked hemoglobin.
The molecular dynamics experiments of chapter four examined the
movement of a crosslinker bound to one lysine residue in oxyhemoglobin, but it
also suggested a possible mode of interaction. Several modifications of the
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molecular dynamics experiments were made, such as lengthening the number of
iterations of the experiment, changing the charges on the interacting lysines, and
enlarging the subset so as to allow more residues to move. These experiments
suggested a probable two step mechanism of crosslinking: 1) one side of DBSF
binds to one

~82

lysine, and 2) then the other

~82

lysine comes in close contact

with the remaining salicyl group because of the electrostatic interactions between
the acid group on DBSF and the amino group of the lysine, to complete the
crosslinking. Therefore, the molecular dynamics experiments demonstrated what
may be happening in the protein in a more realistic manner rather than observing
a static protein.
The last portion of this thesis was devoted to developing a new
photoaffinity crosslinker for hemoglobin. This was accomplished using a variety
of commercially available software programs. The initial problem was to find a
program which could reproduce the binding of a known ligand in hemoglobin.
This was accomplished using the Dock program with bezafibrate analogues
being placed into the a99 site of deoxyhemoglobin. The procedure to develop a
new crosslinker involved the use of such programs as Grid and Ludi. After the
new ligand was developed, it was docked into the deoxy a99 site to examine the
feasibility of binding in this site. The ligand was placed in the proposed site
several times making the strong hydrogen bonds as initially proposed. This
concluded an attempt to develop a new photoaffinity crosslinker for hemoglobin
using molecular modeling techniques.
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